Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder Questions: 1 - 23

Specify the new malignancy1

Acute myeloid leukemia (AML / ANLL)

Other leukemia

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasm (MPN)

Myelodysplasia / myeloproliferative neoplasm (MDS / MPN)

Hodgkin lymphoma

Non-Hodgkin lymphoma

Post-transplant lymphoproliferative disorder (PTLD)

Clonal cytogenetic abnormality without leukemia or MDS

Uncontrolled proliferation of donor cells without malignant transformation

Breast cancer

Central nervous system (CNS) malignancy (e.g. glioblastoma, astrocytoma)

Gastrointestinal malignancy (e.g. colon, rectum, stomach, pancreas, intestine)

Genitourinary malignancy (e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Lung cancer

Melanoma

Basal cell skin malignancy

Squamous cell skin malignancy

Oropharyngeal cancer (e.g. tongue, buccal mucosa)

Sarcoma

Thyroid cancer

Other new malignancy

Specify other new malignancy:2

Date of diagnosis:3 __ __ __ __ - __ __- __ __

Was the new malignancy donor / cell product derived?

Yes No Not done

4

Was documentation submitted to the CIBMTR? (e.g. cell origin evaluation (VNTR, cytogenetics, FISH))

Yes No

5

Was documentation submitted to the CIBMTR? (e.g. pathology report, autopsy report)

yes no

6

Was there EBV reactivation in the blood?

Yes No Unknown

7

How was EBV reactivation diagnosed?8

Qualitative PCR of blood

Quantitative PCR of blood

Other method

Specify other method:9

Quantitative EBV viral load of blood: (at diagnosis of EBV)10 copies/mL

Was a quantitative PCR of blood performed again after diagnosis?

Yes No

11

Highest EBV viral load of blood:12 copies/mL

Was there lymphomatous involvement? (e.g. a mass)

Yes No

13

Bone marrow

yes no

14

Central nervous system (brain or cerebrospinal fluid)

Yes No

15

Liver

yes no

16

Lung

yes no

17

Lymph nodes

yes no

18

Spleen

yes no

19

Other site

yes no

20

Specify other site:21

Was PTLD confirmed by biopsy?

Yes No

22

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

23

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

A separate form 3500 must be submitted to report each new malignancy diagnosed since the date of last report.  The submission of a pathology report or other supportive
documentation for each reported new malignancy is strongly recommended.

Post-Transplant Lymphoproliferative Disorder

Specify sites of PTLD involvement:

Center: CRID: 

Form 3500 R1.0: Subsequent Neoplasms

CIBMTR Form 3500 revision 1.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 2



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder Questions: 1 - 23

Specify the new malignancy1

Acute myeloid leukemia (AML / ANLL)

Other leukemia

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasm (MPN)

Myelodysplasia / myeloproliferative neoplasm (MDS / MPN)

Hodgkin lymphoma

Non-Hodgkin lymphoma

Post-transplant lymphoproliferative disorder (PTLD)

Clonal cytogenetic abnormality without leukemia or MDS

Uncontrolled proliferation of donor cells without malignant transformation

Breast cancer

Central nervous system (CNS) malignancy (e.g. glioblastoma, astrocytoma)

Gastrointestinal malignancy (e.g. colon, rectum, stomach, pancreas, intestine)

Genitourinary malignancy (e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

Lung cancer

Melanoma

Basal cell skin malignancy

Squamous cell skin malignancy

Oropharyngeal cancer (e.g. tongue, buccal mucosa)

Sarcoma

Thyroid cancer

Other new malignancy

Specify other new malignancy:2

Date of diagnosis:3 __ __ __ __ - __ __- __ __

Was the new malignancy donor / cell product derived?

Yes No Not done

4

Was documentation submitted to the CIBMTR? (e.g. cell origin evaluation (VNTR, cytogenetics, FISH))

Yes No

5

Was documentation submitted to the CIBMTR? (e.g. pathology report, autopsy report)

yes no

6

Was there EBV reactivation in the blood?

Yes No Unknown

7

How was EBV reactivation diagnosed?8

Qualitative PCR of blood

Quantitative PCR of blood

Other method

Specify other method:9

Quantitative EBV viral load of blood: (at diagnosis of EBV)10 copies/mL

Was a quantitative PCR of blood performed again after diagnosis?

Yes No

11

Highest EBV viral load of blood:12 copies/mL

Was there lymphomatous involvement? (e.g. a mass)

Yes No

13

Bone marrow

yes no

14

Central nervous system (brain or cerebrospinal fluid)

Yes No

15

Liver

yes no

16

Lung

yes no

17

Lymph nodes

yes no

18

Spleen

yes no

19

Other site

yes no

20

Specify other site:21

Was PTLD confirmed by biopsy?

Yes No

22

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

23

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

A separate form 3500 must be submitted to report each new malignancy diagnosed since the date of last report.  The submission of a pathology report or other supportive
documentation for each reported new malignancy is strongly recommended.

Post-Transplant Lymphoproliferative Disorder

Specify sites of PTLD involvement:

Center: CRID: 

Form 3500 R1.0: Subsequent Neoplasms

CIBMTR Form 3500 revision 1.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 2